Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15097163 | 0.78 | POLB (0.43) | POLBCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL7901443 | 0.78 | POLB (0.43) | POLBPER2MAPTLMNA | |
| SCHEMBL7027351 | 0.76 | POLB (0.58) | POLBCHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL14275610 | 0.76 | POLB (0.53) | POLBKDM4EMAPTRXRARXRB | |
| SCHEMBL10227031 | 0.76 | POLB (0.53) | POLBKDM4EMAPTRXRARXRB | |
| SCHEMBL25007541 | 0.74 | POLB (0.33) | POLBCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21091607 | 0.73 | POLB (0.33) | POLB | |
| SCHEMBL3973891 | 0.72 | POLB (0.46) | POLBKDM4EMAPTRXRARXRB | |
| SCHEMBL13657304 | 0.72 | POLB (0.50) | POLBKDM4EPER2MAPTRXRA | |
| SCHEMBL23183559 | 0.72 | POLB (0.50) | POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-20210371388-A1 | Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection | THE BARUCH S. BLUMBERG INSTITUTE | 2021-12-02 | — | — | US | disclosed |
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2018-01-18 | — | — | US | disclosed |
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2018-01-18 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | POLB 594/4885CHRM2 4876/4885CHRM4 4883/4885 |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | CYP2B6, CBR3, CYP2A6 | POLB 4588/4885CHRM2 39/4885CHRM4 11/4885 |
| US-20210371388-A1 | Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection | EFTUD2, UGP2, UMPS | POLB 185/4885CHRM2 3746/4885CHRM4 3162/4885 |
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, SLC9A1 | POLB 4703/4885CHRM2 1737/4885CHRM4 2630/4885 |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | POLB 4407/4885CHRM2 311/4885CHRM4 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.